26
|
Löb S, Ochmann B, Ma Z, Vilsmaier T, Kuhn C, Schmoeckel E, Herbert SL, Kolben T, Wöckel A, Mahner S, Jeschke U. The role of Interleukin-18 in recurrent early pregnancy loss. J Reprod Immunol 2021; 148:103432. [PMID: 34627076 DOI: 10.1016/j.jri.2021.103432] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2021] [Revised: 09/11/2021] [Accepted: 10/01/2021] [Indexed: 10/20/2022]
Abstract
BACKGROUND A successful pregnancy is a unique and complex immunological state. Cytokines seem to be crucial for the implementation of a tolerogenic environment at the feto-maternal interphase towards the semi-allogenic fetus. Importantly, the switch from a Th1- to a Th2 cytokine profile might play a key role. Interestingly, Interleukin-18 (IL-18) can induce either Th1 or Th2 immune response depending on the local cytokine environment. Therefore, this study investigates the expression of IL-18 in early pregnancy loss. PATIENTS AND METHODS The TaqMan® Human Cytokine Network Array was carried out with placental tissue of patients with healthy pregnancies (n = 15) and recurrent miscarriage (n = 15) in order to investigate differences in IL-18 mRNA expression. Immunohistochemical staining was applied to examine the IL-18 protein expression in the syncytiotrophoblast and decidua of healthy pregnancies (n = 15), spontaneous (n = 12) and recurrent miscarriage (n = 9). The characterization of IL-18 expressing cells in the decidua was evaluated by double-immunofluorescence. Correlation analysis between IL-18 protein expression and clinical data of the study population was performed via spearman correlation coefficient. RESULTS Gene expression analysis revealed a 4,9-times higher expression of IL-18 in recurrent miscarriage patients. IL-18 protein expression was significantly upregulated only in the decidua in the recurrent miscarriage group (p = 0.031). We did not observe significant changes of IL-18 protein expression in spontaneous miscarriage specimens when compared to healthy controls (p = 0.172). Double-immunofluorescence identified decidual stroma cells as IL-18 expressing cells. Correlation analysis showed a significant negative correlation of IL-18 protein expression and gestational age in healthy controls (r = -,745, p = 0.034). Also, a positive correlation of IL-18 and maternal age was observed in patients suffering from recurrent pregnancy loss (r =, 894, p = 0.041). CONCLUSION Our results indicate that IL-18 expression might be necessary in early gestation but requires a tight regulation for a successful ongoing pregnancy. In the present study we observed that a significant upregulation of IL-18 in the decidua was restricted to patients with recurrent miscarriage and therefore might be interesting as a diagnostic marker. Further studies need to evaluate the exact pathophysiological mechanisms.
Collapse
|
27
|
Karsten N, Kolben T, Mahner S, Beyer S, Meister S, Kuhn C, Schmoeckel E, Wuerstlein R, Harbeck N, Ditsch N, Jeschke U, Friese K, Kolben TM. The role of E-Cadherin expression in primary site of breast cancer. Arch Gynecol Obstet 2021; 305:913-920. [PMID: 34510244 PMCID: PMC8967771 DOI: 10.1007/s00404-021-06198-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2021] [Accepted: 08/17/2021] [Indexed: 12/15/2022]
Abstract
PURPOSE The tumour's ability to metastasize is the major cause for fatal outcomes in cancer diseases. In breast cancer, aberrant E-Cadherin expression has been linked to invasiveness and poor prognosis. METHOD We assessed expression of E-Cadherin by immunohistochemistry in primary tumour tissue from 125 female breast cancer patients. Staining intensities were analysed using the immunoreactive score (IRS). We investigated E-Cadherin expression and its associations with clinicopathological parameters (age, tumour size, lymph node status, grade, hormone receptors, Her2 Status) as well as with recurrence and survival. RESULTS Increased, rather than aberrant E-Cadherin expression was found and was associated with poor outcome (p = 0.046). Our data show an association between elevated E-Cadherin in primary tumour tissue and an unfavourable negative prognosis in patients. CONCLUSION This association was somehow unexpected as loss of E-Cadherin has long been regarded as a prerequisite for development of invasiveness and metastases. Our findings support the notion that E-Cadherin promotes, rather than suppresses, development of metastasis and invasiveness.
Collapse
|
28
|
Deuster E, Hysenaj I, Kahaly M, Schmoeckel E, Mayr D, Beyer S, Kolben T, Hester A, Kraus F, Chelariu-Raicu A, Burges A, Mahner S, Jeschke U, Trillsch F, Czogalla B. The Platelet-Activating Factor Receptor's Association with the Outcome of Ovarian Cancer Patients and Its Experimental Inhibition by Rupatadine. Cells 2021; 10:cells10092337. [PMID: 34571986 PMCID: PMC8466210 DOI: 10.3390/cells10092337] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Revised: 08/17/2021] [Accepted: 08/26/2021] [Indexed: 12/20/2022] Open
Abstract
The platelet-activating factor receptor (PAFR) and its ligand (PAF) are important inflammatory mediators that are overexpressed in ovarian cancer. The receptor is an important player in ovarian cancer development. In this study, we aimed to evaluate the prognostic value of PAFR in epithelial ovarian cancer (EOC) and the potential use of its antagonist, rupatadine, as an experimental treatment. Tissue microarrays of ovarian cancer patients, most markedly those with a non-mucinous subtype, immunohistochemically overexpressed PAFR. Elevated cytoplasmic PAFR expression was found to significantly and independently impair patients' overall and recurrence-free survival (OS: median 83.48 vs. 155.03 months; p = 0.022; RFS: median 164.46 vs. 78.03 months; p = 0.015). In vitro, the serous ovarian cancer subtypes especially displayed an elevated PAFR gene and protein expression. siRNA knockdown of PAFR decreased cell proliferation significantly, thus confirming the receptor's protumorigenic effect on ovarian cancer cells. The clinically approved PAFR antagonist rupatadine effectively inhibited in vitro cell proliferation and migration of ovarian cancer cells. PAFR is a prognostic marker in ovarian cancer patients and its inhibition through rupatadine may have important therapeutic implications in the therapy of ovarian cancer patients.
Collapse
|
29
|
Vogelsang TLR, Vattai A, Schmoeckel E, Kaltofen T, Chelariu-Raicu A, Zheng M, Mahner S, Mayr D, Jeschke U, Trillsch F. Trace Amine-Associated Receptor 1 (TAAR1) Is a Positive Prognosticator for Epithelial Ovarian Cancer. Int J Mol Sci 2021; 22:ijms22168479. [PMID: 34445181 PMCID: PMC8395182 DOI: 10.3390/ijms22168479] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Revised: 07/29/2021] [Accepted: 08/03/2021] [Indexed: 12/16/2022] Open
Abstract
Trace amine-associated receptor 1 (TAAR1) is a Gαs- protein coupled receptor that plays an important role in the regulation of the immune system and neurotransmission in the CNS. In ovarian cancer cell lines, stimulation of TAAR1 via 3-iodothyronamine (T1AM) reduces cell viability and induces cell death and DNA damage. Aim of this study was to evaluate the prognostic value of TAAR1 on overall survival of ovarian carcinoma patients and the correlation of TAAR1 expression with clinical parameters. Ovarian cancer tissue of n = 156 patients who were diagnosed with epithelial ovarian cancer (serous, n = 110 (high-grade, n = 80; low-grade, n = 24; unknown, n = 6); clear cell, n = 12; endometrioid, n = 21; mucinous, n = 13), and who underwent surgery at the Department of Obstetrics and Gynecology, University Hospital of the Ludwig-Maximilians University Munich, Germany between 1990 and 2002, were analyzed. The tissue was stained immunohistochemically with anti-TAAR1 and evaluated with the semiquantitative immunoreactive score (IRS). TAAR1 expression was correlated with grading, FIGO and TNM-classification, and analyzed via the Spearman’s rank correlation coefficient. Further statistical analysis was obtained using nonparametric Kruskal-Wallis rank-sum test and Mann-Whitney-U-test. This study shows that high TAAR1 expression is a positive prognosticator for overall survival in ovarian cancer patients and is significantly enhanced in low-grade serous carcinomas compared to high-grade serous carcinomas. The influence of TAAR1 as a positive prognosticator on overall survival indicates a potential prognostic relevance of signal transduction of thyroid hormone derivatives in epithelial ovarian cancer. Further studies are required to evaluate TAAR1 and its role in the development of ovarian cancer.
Collapse
|
30
|
Reichenbach J, Schmoeckel E, Mahner S, Trillsch F. Diagnostic workup for endometrioid borderline ovarian tumors (eBOT) requires histopathological evaluation of the uterus. J Ovarian Res 2021; 14:89. [PMID: 34233728 PMCID: PMC8265084 DOI: 10.1186/s13048-021-00839-4] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Accepted: 06/18/2021] [Indexed: 11/16/2022] Open
Abstract
Background For young borderline ovarian tumor (BOT) patients, preservation of the uterus was incorporated as an accepted option into treatment guidelines. For the endometrioid subtype (eBOT) however, adequate histological evaluation is challenging and might be associated with synchronous endometrial disorders or misinterpreted as spread from uterine primaries. Case presentation We report the cases of two young patients with eBOT who underwent treatment according to current guidelines. In both cases, unexpected findings of invasive uterine carcinomas were established in final histopathological evaluation. Conclusions This constellation highlights the challenging diagnostic workup of BOT and underlines that uterine curettage is indispensable for eBOT to exclude uterine primary tumors when fertility preservation is planned. Accordingly, we suggest to include this procedure into recommendations for diagnostic workup and to state the potential risk in treatment guidelines.
Collapse
|
31
|
Vilsmaier T, Amann N, Löb S, Schmoeckel E, Kuhn C, Zati Zehni A, Meister S, Beyer S, Kolben TM, Becker J, Mumm JN, Mahner S, Jeschke U, Kolben T. The decidual expression of Interleukin-7 is upregulated in early pregnancy loss. Am J Reprod Immunol 2021; 86:e13437. [PMID: 33934432 DOI: 10.1111/aji.13437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Revised: 04/01/2021] [Accepted: 04/12/2021] [Indexed: 11/28/2022] Open
Abstract
BACKGROUND Maternal immunological rejection of the semi-allogenic fetus is discussed as one of the significant factors involved in early pregnancy loss. An array of cytokines secreted by both maternal and fetal cells is involved in generating a delicate maternal immune tolerance. Interleukin-7 (IL-7) is discussed to play a key role in pro-inflammatory processes, but there is still limited insight into the pathophysiological input on placentation and embryonic development in early pregnancy loss. PATIENTS AND METHODS Cytokine level differences were identified with quantitative real-time PCR in placental tissue from spontaneous abortions (SA) (n = 18), recurrent spontaneous abortions (RSA) (n = 15), and healthy pregnancies (n = 15) at gestational weeks 7 to 14. Protein expression of IL-7 in the decidua was investigated by immunohistochemistry. IL-7-expressing cells were identified with double-immunofluorescence. RESULTS Decidua of women with RSA expressed almost 51-times higher values of IL-7 in gene expression analysis. Immunohistochemistry identified a significant upregulation of IL-7 in the decidua of RSA specimens (p = .013) and in the decidua of women with SA (p = .004). Double-immunofluorescence confirmed decidual stroma cells as IL-7-expressing cells. CONCLUSION Significantly elevated IL-7 values in the decidua of spontaneous and recurrent miscarriages imply a crucial role of the cytokine in the signaling at the feto-maternal interface of the placenta. An overexpression of IL-7 could result in early pregnancy loss by inducing a pro-inflammatory environment. Proven to be valuable in other autoimmune diseases, targeting IL-7 signaling therapeutically may prove to be a very beneficial treatment option for RSA patients.
Collapse
|
32
|
Höhn AK, Brambs CE, Erber R, Hiller GGR, Mayr D, Schmidt D, Schmoeckel E, Horn LC. [Reporting and handling of lymphonodectomy specimens in gynecologic malignancies and sentinel lymph nodes]. DER PATHOLOGE 2021; 42:319-327. [PMID: 32700061 PMCID: PMC8084808 DOI: 10.1007/s00292-020-00805-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Abstract
Die Aufarbeitung von Lymphonodektomiepräparaten gynäkologischer Malignome orientiert sich an den nationalen AWMF-Leitlinien und internationalen Empfehlungen. Die Definition von Mikrometastasen und isolierten Tumorzellen entspricht den Festlegungen der UICC(Union Internationale Contre le Cancer)/TNM(TNM-Klassifikation maligner Tumoren). Deren Nachweis soll im Befundbericht erwähnt werden sowie in die Tumorklassifikation einfließen. Alle übersandten Lymphknoten (LK) sollen untersucht werden mit vollständiger Einbettung aller LK bis 0,3 cm und Lamellierung aller größeren Lymphknoten parallel zu ihrer kurzen Achse in ca. 0,2 cm dicken Scheiben. Bestandteile des histologischen Befundberichtes sind: Zahl der befallenen LK im Verhältnis zur Zahl der entfernten/untersuchten LK entsprechend der Entnahmelokalisationen, metrische Ausdehnung der größten LK-Metastase, Fehlen/Nachweis einer extrakapsulären Ausbreitung. Zuschnitt und Einbettung von Sentinel-LK mit oder ohne Schnellschnittuntersuchung erfolgt in Analogie zu Nicht-Sentinel-LK mit Anfertigung von ca. 3 HE-gefärbten Stufenschnitten in einem Abstand von ca. 200 µm sowohl vom Gefrier- als auch Paraffinblock. Stellen sich die Sentinel-LK in der HE-Färbung negativ dar, soll ein immunhistochemisches Ultrastaging erfolgen.
Collapse
|
33
|
Beilner D, Kuhn C, Kost BP, Vilsmaier T, Vattai A, Kaltofen T, Mahner S, Schmoeckel E, Dannecker C, Jückstock J, Mayr D, Jeschke U, Heidegger HH. Nuclear receptor corepressor (NCoR) is a positive prognosticator for cervical cancer. Arch Gynecol Obstet 2021; 304:1307-1314. [PMID: 33861372 PMCID: PMC8490237 DOI: 10.1007/s00404-021-06053-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Accepted: 03/27/2021] [Indexed: 12/19/2022]
Abstract
Purpose Enzymes with epigenetic functions play an essential part in development of cancer. However, the significance of epigenetic changes in cervical carcinoma as a prognostic factor has not been fully investigated. Nuclear receptor corepressor (NCoR) presents itself as a potentially important element for epigenetic modification and as a potential prognostic aspect in cervical cancer. Methods By immunohistochemical staining of 250 tumor samples, the expression strength of NCoR was measured and evaluated by immunoreactive score (IRS) in the nucleus and cytoplasm. Results A low expression of NCoR in our patients was a disadvantage in overall survival. Expression of NCoR was negatively correlated with viral oncoprotein E6, acetylated histone H3 acetyl K9 and FIGO status, and positively correlated to p53. Conclusions Our study has identified epigenetic modification of tumor cells thus seems to be of relevance in cervical cancer as well for diagnosis, as a marker or as a potential therapeutic target in patients with advanced cervical carcinoma.
Collapse
|
34
|
Lin L, Kuhn C, Ditsch N, Kolben T, Czogalla B, Beyer S, Trillsch F, Schmoeckel E, Mayr D, Mahner S, Jeschke U, Hester A. Breast adipose tissue macrophages (BATMs) have a stronger correlation with breast cancer survival than breast tumor stroma macrophages (BTSMs). Breast Cancer Res 2021; 23:45. [PMID: 33849622 PMCID: PMC8042723 DOI: 10.1186/s13058-021-01422-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Accepted: 03/23/2021] [Indexed: 12/31/2022] Open
Abstract
Background An abundance of tumor-associated macrophages has been shown to be an independent prognostic factor for a poor prognosis of human breast cancer (BC). Adipose tissue accounts for the largest proportion of the breast and has also been identified as an independent indicator of poor survival in BC. This study aims to elucidate if the influence of adipose tissue in BC might be mediated by macrophages. The roles of macrophages in the breast tumor-stroma (breast tumor stroma macrophages, BTSM) and macrophages in the surrounding adipose tissue (breast adipose tissue macrophages, BATM) were explored separately. Methods Two hundred ninety-eight BC tissue samples were analyzed immunohistochemically. The number of macrophages was detected by CD68+ staining. The quantity of BATMs and BTSMs was correlated to clinical and pathological parameters as well as to disease-free survival (DFS) and overall survival (OS). Results The amounts of BATMs and BTSMs strongly correlated with each other (r = 0.5, p = 2.98E−15). The quantity of BTSMs, but not of BATMs, was significantly associated with the BC molecular subtype (p = 0.000011), and all triple-negative BC tumors contained high amounts of BTSMs. BATMs were negatively associated with DFS (p = 0.0332). Both BATMs (p = 0.000401) and BTSMs (p = 0.021) were negatively associated with OS in the Kaplan-Meier analysis, but only BATMs remained an independent factor in the multivariate Cox-regression analysis (HR = 4.464, p = 0.004). Combining prostaglandin E2 receptor 3 (EP3)-expression and the quantity of BATMs, a subgroup with an extremely poor prognosis could be identified (median OS 2.31 years in the “high BATMs/low EP3” subgroup compared to 11.42 years in the most favorable “low BATMs/high EP3” subgroup, p = 0.000002). Conclusion Our findings suggest that BTSMs and BATMs seem to be involved differently in BC. Breast adipose tissue might contribute to the aggressiveness of BC via BATMs, which were independently associated with BC survival. BATMs’ role and occurrence might be functionally dependent on EP3, as a combination of both factors was strongly associated with survival. Targeting BATMs—eventually in combination with targeting the EP3-pathway—might be promising for future therapies. Supplementary Information The online version contains supplementary material available at 10.1186/s13058-021-01422-x.
Collapse
|
35
|
Mayr D, Schmoeckel E, Höhn AK, Hiller GGR, Horn LC. [Current WHO classification of the female genitals : Many new things, but also some old]. DER PATHOLOGE 2021; 42:259-269. [PMID: 33822250 DOI: 10.1007/s00292-021-00933-w] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 03/08/2021] [Indexed: 02/06/2023]
Abstract
The new WHO classification of tumors of the female genitalia entails some changes, especially those of prognostic and therapeutic relevance: there is a return to the term borderline tumor. Implants are again subdivided into noninvasive implants of the epithelial or desmoplastic type as before. Invasive extraovarian implants are classified as low-grade serous carcinoma (LGSC). Former seromucinous carcinomas are now classified as endometrioid carcinomas (seromucinous subtype). New entities of ovarian carcinomas are mesonephric-like adenocarcinoma, undifferentiated and dedifferentiated carcinoma, and mixed carcinoma. The classification of neuroendocrine neoplasms is analogous to that of pulmonary and gastrointestinal neuroendocrine neoplasms, regardless of their location. Endometrioid endometrial carcinoma can be classified into four molecular subtypes, which have significant prognostic significance. New subtypes include mucinous carcinoma of the intestinal type and mesonephric-like adenocarcinoma. Stromasarcomas of the endometrium are further subclassified based on specific molecular alterations. Adenocarcinomas (ACs) and squamous cell carcinomas (PECs) of the lower female genital tract are distinguished from HPV-associated and HPV-independent carcinomas. Block-like staining for p16 is the accepted surrogate immunohistochemical marker. Grading has not been reported for PEC. For HPV-associated AC of the cervix uteri, prognostic assessment is based on the pattern of invasion (so-called Silva pattern). Serous carcinomas in the cervix uteri are endometrial carcinomas with cervical infiltration.
Collapse
|
36
|
Dimpfl M, Degenhardt T, Mayr D, Schmoeckel E, Harbeck N, Wuerstlein R. Abstract PS13-32: Hormone- and HER2 receptor change in non-pCR breast cancer specimens after neoadjuvant treatment. Cancer Res 2021. [DOI: 10.1158/1538-7445.sabcs20-ps13-32] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Introduction: This study aimed at identification of breast cancer patients with a switched hormone- or HER2 receptor status after neoadjuvant chemotherapy. Therefore, patients without pathological complete response (pCR) were evaluated. The hormone and HER2 receptor status determined prior to neoadjuvant chemotherapy was compared with the corresponding receptor status determined in the surgical specimen after neoadjuvant chemotherapy.
Methods: Clinicopathological data of 249 patients, who received neoadjuvant treatment between 2016 and 2019 at the LMU breast center, Munich were reviewed. Among those, 129 patients (52%) with non-pCR were identified. Of those, 11 patients had a residual positive lymph node only. pCR was defined as absence of invasive tumor in breast and lymph node (ypT0/is; ypN0). According to German clinical guidelines, specimens were labeled hormone receptor positive, if ≥1% of tumor nuclei were reported estrogen receptor positive or ≥10% of tumor nuclei were reported progesterone receptor positive. Tumors were labeled HER2-positive if immunohistochemistry showed strong complete circular membrane staining of >10% of invasive cells or if in-situ-hybridization showed HER2 positivity. Surgical specimens of patients with non-pCR were pathologically evaluated in order to 1) detect a receptor status switch compared to the analysis prior to neoadjuvant chemotherapy and 2) to see whether additional post neoadjuvant treatment options become available.
Results: The following results apply exclusively to non-pCR cases. Median age at diagnosis was 51 years, 27 patients were younger than 40. One male patient is included.A total of 36 cases (28%) switched either hormone- or HER2-status, including two cases of a simultaneous switch. In 19 cases, the hormone receptor status switched. 3 patients switched from hormone receptor negative to positive, while 16 switched from hormone receptor positive to negative. A total of 17 cases showed a switch in HER2 receptor status. 6 patients switched from HER2-negative to HER2-positive, while 11 switched from HER2-positive to HER2-negative. Due to technical limitations, HER2 status was not evaluable in two cases, and hormone receptor status in one case. See table below.
Conclusion: Our results illustrate, that a biomarker status switch after neoadjuvant treatment occurs in almost a third (28%) of cases. Reassessment of hormone- and HER2-receptor status subsequent to neoadjuvant treatment is still under discussion, with regard to post-neoadjuvant treatment. Nevertheless, it may have potential benefits for patients regarding individualization of treatment and potentially even patient outcome. At present, only gain of receptors should impact treatment concepts; in case of loss of receptors, treatment should not be changed as results in the residual tumor tissue may not reflect receptor status on disseminated tumor cells.
Biomarker status in patients with non-pCRBiomarrker status in patients with non-pCRStatus at initial diagnosisStatus in surgical non-pCR specimenCases with switch in biomarker status after NACHR positive99 (77%)85 (66%)3HR negative30 (23%)43 (34%)16HR total12912819 (15%)HER2 positive35 (27%)28 (22%)6HER2 negative94 (73%)99 (78%)11HER2 total12912717 (13%)Cases with switch in biomarker status36 (28%)
Citation Format: Moritz Dimpfl, Tom Degenhardt, Doris Mayr, Elisa Schmoeckel, Nadia Harbeck, Rachel Wuerstlein. Hormone- and HER2 receptor change in non-pCR breast cancer specimens after neoadjuvant treatment [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS13-32.
Collapse
|
37
|
Löb S, Vattai A, Kuhn C, Schmoeckel E, Mahner S, Wöckel A, Kolben T, Keil C, Jeschke U, Vilsmaier T. Pregnancy Zone Protein (PZP) is significantly upregulated in the decidua of recurrent and spontaneous miscarriage and negatively correlated to Glycodelin A (GdA). J Reprod Immunol 2020; 143:103267. [PMID: 33388716 DOI: 10.1016/j.jri.2020.103267] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Revised: 11/10/2020] [Accepted: 12/16/2020] [Indexed: 12/19/2022]
Abstract
BACKGROUND Pregnancy Zone Protein (PZP) is an immunosuppressive protein that is expressed by the placenta and has also been identified in immune cells. When PZP and Glycodelin A (GdA) are combined, they act synergistically to inhibit Th-1 immune response. Little is known about its combined expression and role in normal and disturbed first trimester pregnancy. PATIENTS AND METHODS We investigated the expression of PZP and GdA in placental tissue obtained from spontaneous miscarriage (SM) (n = 19) and recurrent miscarriage (RM) (n = 17) at gestational weeks 6-13 by immunohistochemistry and on mRNA-level by either TaqMan PCR or in situ hybridization. Placental tissue from legal terminations of healthy pregnancies (n = 15) served as control group. Immunofluorescence double staining was used to analyse the combined expression of PZP and GdA in decidual tissue. RESULTS The protein level of PZP was significantly increased in decidual stroma of SM samples compared to the decidua of control specimens and also significantly upregulated in the decidual stroma cells in the RM group. Concerning GdA, the decidual stroma revealed a significantly decreased protein level in the group with spontaneous abortions than in the group with healthy pregnancies. There was also a significant downregulation of GdA in the decidual stroma of RM samples compared to the control group. We observed a significant negative correlation of PZP and GdA in decidual stromal tissue of recurrent abortion. We could confirm the staining results for PZP as well as for GdA on mRNA level. Both proteins are co-localized in decidual stroma as analysed by immunofluorescence double staining. CONCLUSION A balanced expression of GdA and its carrier protein PZP in the decidua seems crucial for a successful ongoing pregnancy. According to our data, these immunosuppressive proteins are co-localized in the decidual tissue and show a negative correlation only in patients suffering from recurrent abortion.
Collapse
|
38
|
Wanka G, Schmoeckel E, Mayr D, Fuerst S, Kuhn C, Mahner S, Knabl J, Karsten MM, Dannecker C, Heidegger HH, Vattai A, Jeschke U, Jueckstock J. LDOC1 as Negative Prognostic Marker for Vulvar Cancer Patients. Int J Mol Sci 2020; 21:ijms21239287. [PMID: 33291445 PMCID: PMC7730493 DOI: 10.3390/ijms21239287] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2020] [Revised: 12/02/2020] [Accepted: 12/03/2020] [Indexed: 12/13/2022] Open
Abstract
So far, studies about targeted therapies and predictive biomarkers for vulva carcinomas are rare. The leucine zipper downregulated in cancer 1 gene (LDOC1) has been identified in various carcinomas as a tumor-relevant protein influencing patients' survival and prognosis. Due to the lack of information about LDOC1 and its exact functionality, this study focuses on the expression of LDOC1 in vulvar carcinoma cells and its surrounding immune cells as well as its correlation to clinicopathological characteristics and prognosis. Additionally, a possible regulation of LDOC1 in vulvar cancer cell lines via the NF-κB signaling pathway was analyzed. Vulvar carcinoma sections of 157 patients were immunohistochemically stained and examined regarding LDOC1 expression by using the immunoreactive score (IRS). To characterize LDOC1-positively stained immune cell subpopulations, immunofluorescence double staining was performed. The effect of the NF-κB inhibitor C-DIM 12 (3,3'-[(4-chlorophenyl)methylene]bis[1 H-indole]) on vulvar cancer cell lines A431 and SW 954 was measured according to MTT and BrdU assays. Baseline expression levels of LDOC1 in the vulvar cancer cell lines A431 and SW 954 was analyzed by real-time PCR. LDOC1 was expressed by about 90% of the cancer cells in the cytoplasm and about half of the cells in the nucleus. Cytoplasmatic expression of LDOC1 was associated with decreased ten-year overall survival of the patient, whereas nuclear staining showed a negative association with disease-free survival. Infiltrating immune cells were mainly macrophages followed by regulatory T cells. Incubation with C-DIM 12 decreased the cell viability and proliferation of vulvar cancer cell line A431, but not of cell line SW 954. LDOC1 expression on mRNA level was twice as high in the cell line A431 compared to the cell line SW 954. Overexpression of LDOC1 was associated with unfavorable overall and disease-free survival. Tumor growth could be inhibited by C-DIM 12 in vitro if the expressed LDOC1 level was high enough.
Collapse
|
39
|
Czogalla B, Partenheimer A, Badmann S, Schmoeckel E, Mayr D, Kolben T, Beyer S, Hester A, Burges A, Mahner S, Jeschke U, Trillsch F. Nuclear Enolase-1/ MBP-1 expression and its association with the Wnt signaling in epithelial ovarian cancer. Transl Oncol 2020; 14:100910. [PMID: 33069100 PMCID: PMC7569221 DOI: 10.1016/j.tranon.2020.100910] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Revised: 09/28/2020] [Accepted: 10/05/2020] [Indexed: 12/30/2022] Open
Abstract
BACKGROUND Enolase-1, primarily known for its role in glucose metabolism, is overexpressed in various cancer entities. In contrast its alternative spliced nuclear isoform MBP-1 acts as a tumor suppressor. The aim of this study is to analyze the prognostic impact of Enolase-1/ MBP-1 and its functional significance in epithelial ovarian cancer (EOC). METHODS By immunohistochemistry, Enolase-1 staining was examined in 156 EOC samples. Evaluation of Enolase-1 staining was conducted in the nucleus and the cytoplasm using the semi-quantitative immunoreactive score. Expression levels were correlated with clinical and pathological parameters as well as with overall survival to assess for prognostic impact. RESULTS Cytoplasmic and nuclear Enolase-1 expression did not show a significant difference between the histological subtypes (p = 0.1). High nuclear Enolase-1/ MBP-1 staining negativly correlated with the tumor grading (p<0.001; Cc= -0.318). Cytoplasmic Enolase-1 did not correlate with clinicopathological data. Higher nuclear Enolase-1/ MBP-1 staining was detected in low-grade serous cancer cases compared to high-grade ones (median IRS 3 (range 0-8) vs. median IRS 2 (range 0-4), p<0.001). Nuclear Enolase-1/ MBP-1 expression correlated with the Wnt signaling markers membranous beta-catenin (p = 0.007; Cc=0.235), serine residue 9-phosphorylated glycogen synthase kinase 3 beta (p<0.001; Cc=0.341) and snail/slug (p = 0.004; Cc= -0.257). High nuclear Enolase-1/ MBP-1 expression was associated with improved overall survival (88.6 vs. 33.1 months, median; p = 0.013). CONCLUSION Additional knowledge of Enolase-1/ MBP-1 as a biomarker and its interactions within the Wnt signaling pathway and epithelial-mesenchymal transition potentially improve the prognosis of therapeutic approaches in EOC.
Collapse
|
40
|
Mannewitz M, Beyer S, Meister S, Kolben T, Schmoeckel E, Mayr D, Anz D, Perleberg C, Burges A, Trillsch F, Vattai A, Czogalla B, Corradini S, Mahner S, Jeschke U, Kolben T. Impact of monocyte- and macrophage- derived CCL22 on endometrial cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718161] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
41
|
Liao Y, Badmann S, Kaltofen T, Mayr D, Schmoeckel E, Deuster E, Mannewitz M, Landgrebe S, Kolben T, Hester A, Beyer S, Burges A, Mahner S, Jeschke U, Trillsch F, Czogalla B. PLA2G7/PAF-AH as protective factor and potential negative regulator of the Wnt signaling pathway in BRCA1 mutant ovarian cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718211] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
42
|
Hahn L, Beyer S, Kolben T, Schmoeckel E, Mayr D, Anz D, Kuhn C, Vattai A, Hester A, Corradini S, Hasbargen U, Mahner S, Jeschke U, Meister S, Kolben T. Verminderte Rekrutierung regulatorischer T-Zellen bei erhöhter CCL22-Expression in der Präeklampsie. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
43
|
Heublein S, Jeschke U, Sattler C, Kuhn C, Hester A, Czogalla B, Trillsch F, Mahner S, Mayr D, Schmoeckel E, Ditsch N. Subcellular localization of thyroid hormone receptor beta is associated with grade, FIGO stage and disease outcome in ovarian cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
44
|
Liao Y, Mayr D, Schmoeckel E, Hester A, Kolben T, Zeder-Göß C, Würstlein R, Harbeck N, Mahner S, Jeschke U, Trillsch F, Czogalla B. Interaction of PAFAH and beta-catenin in BRCA1 mutant breast cancer. Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)30735-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
45
|
Badmann S, Mayr D, Schmoeckel E, Hester A, Kolben T, Beyer S, Burges A, Mahner S, Jeschke U, Trillsch F, Czogalla B. AKR1C1/2 inhibition by MPA resensitizes platinum resistant ovarian cancer towards platinum-based chemotherapy. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
46
|
Wehrmann M, Beyer S, Meister S, Kolben TM, Schmoeckel E, Mayr D, Burges A, Trillsch F, Vattai A, Hester A, Mahner S, Jeschke U, Kolben T. Galectin-8 and -9 as prognostic factors for cervical cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718196] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
47
|
Wehrmann M, Kolben T, Meister S, Kolben TM, Schmoeckel E, Mayr D, Burges A, Trillsch F, Vattai A, Hester A, Mahner S, Jeschke U, Beyer S. Gal-8, Gal-9, Histone H3-Acetyl-K9, Histone H3-Trimethyl-K4 and Glucocorticoid Receptor as possible prognostic markers in endometrial cancer. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
48
|
Vogelsang TLR, Schmoeckel E, Kuhn C, Blankenstein T, Temelkov M, Heidegger H, Kolben TM, Kolben T, Mahner S, Mayr D, Jeschke U, Vattai A. Die Regulation der LCoR und RIP140 Expression in zervikaler intraepithelialer Neoplasie (CIN) und deren Korrelation mit CIN- Progress und Dedifferenzierung. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718195] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
49
|
Meister S, Hahn L, Beyer S, Kolben T, Schmoeckel E, Mayr D, Vattai A, Hester A, Corradini S, Hasbargen U, Mahner S, Jeschke U, Kolben T. Die Rolle epigenetischer Modifikationen in der Präeklampsie im Zusammenhang mit PPARγ (Peroxisom-Proliferator-aktivierter Rezeptor-γ) und Galectin-2. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717949] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
50
|
Trebo A, Ditsch N, Kuhn C, Heidegger H, Zeder-Göß C, Kolben T, Czogalla B, Schmoeckel E, Mahner S, Jeschke U, Hester A. Hohe Galectin-7 und niedrige Galectin-8 Expression und die Kombination aus beiden als prognostisch negative Marker für Brustkrebspatientinnen. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1718191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|